Advertisement

Annals of Hematology

, Volume 90, Issue 10, pp 1191–1200 | Cite as

Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules

  • Peter Loewen
  • Karen Dahri
Original Article

Abstract

This study aimed to determine whether progress in developing bleeding risk estimation tools for patients on oral anticoagulant therapy has been made since 2006 when we last systematically reviewed this topic, and to refresh previously published quantitative evaluations of the clinical prediction rules (CPRs) available for estimating bleeding risk in patients on oral anticoagulant therapy. A systematic review of English language literature published since December 2006 was conducted when our previous systematic review ended. Studies were analyzed for predictive performance using likelihood ratios. Six studies detailed CPRs used to assess risk of bleeding prior to commencing warfarin therapy, four of which were included in the analysis. Three studies evaluated new CPRs (“RIETE” and “HAS-BLED”). One of the studies was a further validation of the modified outpatient bleeding risk index (mOBRI) in patients with atrial fibrillation. Individual trial and pooled analyses using likelihood ratios for mOBRI and HAS-BLED showed they have weak predictive accuracy. A RIETE score of 0 point was moderately predictive of the absence of major bleeding. None of the CPRs exhibited sufficient predictive accuracy or had sufficient validation to be recommended for routine use in practice. None of the available CPRs exhibit sufficient predictive accuracy or have trials evaluating the impact of their use on patient outcomes. Hence, no existing oral anticoagulation major bleeding CPR can be recommended for routine use in practice at present.

Keywords

Bleeding Warfarin Anticoagulants Clinical prediction rules 

Notes

Conflicts of interest

No funding was provided to assist in the preparation of the manuscript. The authors have no potential conflicts of interest to declare.

References

  1. 1.
    Ansell J, Hirsh J, Hylek E et al (2008) The pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133:160S–198SPubMedCrossRefGoogle Scholar
  2. 2.
    Connolly SJ, Ezekowitz MD, Yusuk S, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). N Engl J Med 361.  10.1056/NEJMoa0905561
  3. 3.
    Schulman S, Kearon C, Kakkar AK, et al. (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER). N Engl J Med 361.  10.1056/NEJMoa0906598
  4. 4.
    Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial (RE-NOVATE). Lancet 370:949–956PubMedCrossRefGoogle Scholar
  5. 5.
    Turpie AGG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373:1673–1680PubMedCrossRefGoogle Scholar
  6. 6.
    Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375:807–815PubMedCrossRefGoogle Scholar
  7. 7.
    Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95(3):315–328PubMedCrossRefGoogle Scholar
  8. 8.
    ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation rationale and design of the ROCKET AF study. Am Heart J 159(3):340–347.e.1Google Scholar
  9. 9.
    Gasse C, Hollowell J, Meier CR et al (2005) Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 94(3):537–543PubMedGoogle Scholar
  10. 10.
    Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689–2696PubMedCrossRefGoogle Scholar
  11. 11.
    Dahri K, Loewen P (2007) The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 98:980–987PubMedGoogle Scholar
  12. 12.
    The Cochrane Library. Cochrane reviewers’ handbook 5.0.2. 2009; available at http://www.cochrane-handbook.org. Accessed 12 December 2010
  13. 13.
    Liberati A, Altman DG, Tetzlaff D et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W-65–W-94Google Scholar
  14. 14.
    Sportif III (2003) Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691–1698CrossRefGoogle Scholar
  15. 15.
    Sportif V (2005) Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293:690–698CrossRefGoogle Scholar
  16. 16.
    Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694PubMedCrossRefGoogle Scholar
  17. 17.
    Ingui BJ, Rogers MAM (2001) Searching for clinical prediction rules in Medline. J Am Med Inform Assoc 8(4):391–397PubMedCrossRefGoogle Scholar
  18. 18.
    Laupacis A, Sekar N, Stiell IG (1997) Clinical prediction rules: a review and suggested modifications of methodological standards. JAMA 277(6):488–494PubMedCrossRefGoogle Scholar
  19. 19.
    McGinn TG, Guyatt GH, Wyer PC et al (2000) Users’ guides to the medical literature XXII: how to use articles about clinical decision rules. JAMA 284(1):79–84PubMedCrossRefGoogle Scholar
  20. 20.
    Peirce JC, Cornell RG (1993) Integrating stratum-specific likelihood ratios with the analysis of ROC curves. Med Decis Making 13(2):141–151PubMedCrossRefGoogle Scholar
  21. 21.
    Deeks JJ, Altman DG (2004) Diagnostic tests 4: likelihood ratios. BMJ 329(7458):168–169PubMedCrossRefGoogle Scholar
  22. 22.
    Greenhalgh T (1997) How to read a paper: papers that report diagnostic or screening tests. BMJ 315:540–543PubMedGoogle Scholar
  23. 23.
    Sackett DL, Haynes RB, Guyatt GH, Tugwell P (1991) Clinical epidemiology—a basic science for clinical medicine. London, Little Brown 51–68Google Scholar
  24. 24.
    Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935PubMedCrossRefGoogle Scholar
  25. 25.
    Jaeschke R, Guyatt G, Sackett DL (1994) Users’ guides to the medical literature: III. How to use an article about a diagnostic test: A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 271(5):389–391PubMedCrossRefGoogle Scholar
  26. 26.
    Jaeschke R, Guyatt GH, Sackett DL (1994) User’s guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? JAMA 271(9):703–707PubMedCrossRefGoogle Scholar
  27. 27.
    van der Meer FJM, Rosendaal FR, Vandenbroucke JP et al (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76(1):12–16PubMedGoogle Scholar
  28. 28.
    Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest 138(5):1093–1100PubMedCrossRefGoogle Scholar
  29. 29.
    Lip GYH, Frison L, Halperin JL, Lane DA (2011) Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 57:173–180PubMedCrossRefGoogle Scholar
  30. 30.
    Airaksinen KEJ, Suurmunne H, Porela P et al (2010) Usefulness of outpatient bleeding risk index to predict bleeding complications in patients with long-term oral anticoagulation undergoing coronary stenting. Am J Cardiol 106:175–179PubMedCrossRefGoogle Scholar
  31. 31.
    Ruiz-Giminez N et al (2008) Predictive variables for major bleeding events in patients presenting with document acute venous thromboembolism: findings from the RIETE registry. Thromb Haemost 100:26–31Google Scholar
  32. 32.
    Wess ML, Schauer DP, Johnston JA et al (2007) Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med 23(4):411–417CrossRefGoogle Scholar
  33. 33.
    Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87(2):144–152PubMedCrossRefGoogle Scholar
  34. 34.
    Beyth RJ, Quinn LM, Landefeld CS (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105(2):91–99PubMedCrossRefGoogle Scholar
  35. 35.
    Aspinall SL, DeSanzo BE, Trilli LE et al (2005) Bleeding risk index in an anticoagulation clinic: assessment by indication and implications for care. J Gen Intern Med 20(11):1008–1013PubMedCrossRefGoogle Scholar
  36. 36.
    Wells PS, Forgie MA, Simms M et al (2003) The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163(8):917–920PubMedCrossRefGoogle Scholar
  37. 37.
    Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke. JAMA 285:2864–2870PubMedCrossRefGoogle Scholar
  38. 38.
    Ohman EM, Granger CB, Harrington RA, Lee KL (2000) Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 284:876–878PubMedCrossRefGoogle Scholar
  39. 39.
    Harrell E, Califf R, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247:2543–2546PubMedCrossRefGoogle Scholar
  40. 40.
    Canadian Cardiovascular Society (2010) Canadian Cardiovascular Society 2010 Atrial Fibrillation Guidelines. Available at http://www.ccsguidelineprograms.ca/index.php?option=com_content&view=article&id=111&Itemid=66. Accessed 12 December 2010
  41. 41.
    The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (2010) Guidelines for the management of atrial fibrillation. Eur Heart J 31:2369–2429. doi: 10.1093/eurheartj/ehq278 CrossRefGoogle Scholar
  42. 42.
    Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA (1994) Patient preferences for stroke outcomes. Stroke 25:1721–1725PubMedCrossRefGoogle Scholar
  43. 43.
    Devereaux PJ, Anderson DR, Gardner MJ et al (2001) Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 323:1218–1222CrossRefGoogle Scholar
  44. 44.
    Palareti G, Cosmi B (2009) Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost 102:268–278PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Education & Research, Lower Mainland Pharmacy ServicesUniversity of British ColumbiaVancouverCanada
  2. 2.Vancouver Coastal HealthUniversity of British ColumbiaVancouverCanada
  3. 3.Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada

Personalised recommendations